Home    Back

 157. Sturge-Weber syndrome
 [ 6 clinical trials,    9 drugs(DrugBank: 4 drugs),    5 target genes / 55 target pathways

Searched query = "Sturge Weber syndrome", "Síndrome de Sturge Weber"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03047980January 201726 August 2019Trial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeTrial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeSturge-Weber SyndromeDrug: SirolimusAnne Comi, MDChildren's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting3 Years31 YearsAll10Phase 2/Phase 3United States
2NCT02332655December 201421 January 2019Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeCannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeSturge-Weber SyndromeDrug: CannabidiolAnne Comi, MDGW Pharmaceuticals Ltd.;Faneca 66 FoundationNot recruiting1 Month45 YearsAll10Phase 1/Phase 2United States
3NCT01997255April 201417 May 2016Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber SyndromeSturge Weber SyndromeDrug: EverolimusBaylor College of MedicineNovartis PharmaceuticalsNot recruiting2 Years18 YearsBoth0Phase 2United States
4NCT01533376February 20121 April 2019Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololTreatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololSturge Weber Syndrome;Port-wine MarkDrug: Timolol;Drug: Preservative free artificial tear gel.Wills EyeUniversity of Medicine and Dentistry of New JerseyNot recruiting2 Years10 YearsAll3Phase 1United States
5EUCTR2010-024078-20-ES11/05/201120 March 2012Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberEnsayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberMalformación capilar cutánea en pacientes con síndrome de Sturge-Weber.
MedDRA version: 13 Level: PT Classification code 10042265 Term: Síndrome de Sturge-Weber
Product Name: Rapamicina tópica al 1% y excipiente
Pharmaceutical Form: Cream
INN or Proposed INN: crema de rapamicina al 1% y excipientes
Concentration unit: mg/g milligram(s)/gram
Concentration type: equal
Concentration number: 10-
Product Name: Crema placebo (excipiente)
Pharmaceutical Form: Cream
INN or Proposed INN: Crema placebo (excipiente)
Concentration type: up to
Concentration number: 0-
Pharmaceutical form of the placebo: Cream
Route of administration of the placebo: Topical use (Noncurrent)
Instituto Científico y Tecnológico de NavarraNot RecruitingFemale: yes
Male: yes
Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00639730May 200619 February 2015Use of the Atkins Diet for Children With Sturge Weber SyndromeUse of the Atkins Diet for Children With Sturge Weber SyndromeEpilepsy;Sturge Weber SyndromeDietary Supplement: modified Atkins dietJohns Hopkins UniversityVascular Birthmarks FoundationNot recruiting2 Years18 YearsBoth5Phase 1United States

Back to top